IL6 and synovitis: A single i.a. injection of sTNFRII (0.3 mg) similarly led to significant degenerative changes as it significantly reduced the tibial plateau bone fraction vs. local saline treatment and, while a single i.a. injection of sTNFRII significantly decreased IL-6 in the synovial fluid in both the injured and uninjured knee joints, it significantly increased serum IL-6 and serum CTX-I, and increased the synovitis score.